The notice of allowance for a new US patent is a significant positive development for ReShape Lifesciences, indicating potential for increased market protection and competitive advantage for its intragastric balloon system. This regulatory milestone is likely to boost investor confidence, contributing to the short-term uptick in the company's stock price.